Lipocine Inc. Files 8-K

Ticker: LPCN · Form: 8-K · Filed: 2024-10-02T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, regulatory-filing

TL;DR

Lipocine filed a routine 8-K on Oct 2nd. Nothing major disclosed.

AI Summary

Lipocine Inc. filed an 8-K on October 2, 2024, reporting other events and financial statements. The company, incorporated in Delaware with its principal executive offices in Salt Lake City, Utah, previously operated under the name Marathon Bar Corp until November 30, 2011. The filing does not detail specific financial transactions or events beyond its routine reporting nature.

Why It Matters

This 8-K filing indicates Lipocine Inc. is fulfilling its regulatory reporting obligations, which is standard for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting events and financial statements, with no immediate indication of significant risk or opportunity.

Key Players & Entities

Lipocine Inc. (company) — Registrant
Marathon Bar Corp (company) — Former company name
October 2, 2024 (date) — Date of earliest event reported
675 Arapeen Drive, Suite 202 (location) — Principal executive offices address
Salt Lake City, Utah (location) — Principal executive offices city and state

FAQ

What specific events are being reported in this 8-K filing?

The filing indicates it is for 'Other Events' and 'Financial Statements and Exhibits', but the specific details of these events are not provided in the excerpt.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on October 2, 2024.

What was Lipocine Inc.'s former company name?

Lipocine Inc.'s former company name was Marathon Bar Corp.

On what date did the company change its name from Marathon Bar Corp?

The company changed its name from Marathon Bar Corp on November 30, 2011.

Where are Lipocine Inc.'s principal executive offices located?

Lipocine Inc.'s principal executive offices are located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.

From the Filing

0001493152-24-039133.txt : 20241002 0001493152-24-039133.hdr.sgml : 20241002 20241002093510 ACCESSION NUMBER: 0001493152-24-039133 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20241002 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241002 DATE AS OF CHANGE: 20241002 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lipocine Inc. CENTRAL INDEX KEY: 0001535955 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 990370688 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36357 FILM NUMBER: 241345514 BUSINESS ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 BUSINESS PHONE: 801 994 7383 MAIL ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 FORMER COMPANY: FORMER CONFORMED NAME: MARATHON BAR CORP DATE OF NAME CHANGE: 20111130 8-K 1 form8-k.htm false 0001535955 0001535955 2024-10-02 2024-10-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of Earliest Event Reported): October 2, 2024     LIPOCINE INC. (Exact name of registrant as specified in its charter)   Commission File No. 001-36357   Delaware   99-0370688 (State or other jurisdiction of incorporation)   (IRS Employer Identification Number)   675 Arapeen Drive , Suite 202 Salt Lake City , Utah 84108 (Address of principal executive offices) (Zip Code)   Registrant’s telephone number, including area code: (801) 994-7383   Former name or former address, if changed since last report: Not Applicable       Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   LPCN   The NASDAQ Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 8.01 Other Events   The Company issued a press release announcing that it will host a virtual key opinion leader (“KOL”) event on LPCN 2401 for improved body composition in obesity management on Wednesday, October 16, 2024, at 11:00AM ET. The press release is filed as Exhibit 99.1.   Item 9.01 Financial Statements and Exhibits.   (d) Exhibits   The following exhibits are filed with this report:   Exhibit No.   Description       99.1   Press Release announcing Lipocine